BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 1450072)

  • 1. Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease.
    Henry-Amar M
    Ann Oncol; 1992 Sep; 3 Suppl 4():117-28. PubMed ID: 1450072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome.
    Mauch PM; Kalish LA; Marcus KC; Coleman CN; Shulman LN; Krill E; Come S; Silver B; Canellos GP; Tarbell NJ
    Blood; 1996 May; 87(9):3625-32. PubMed ID: 8611686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second cancer risk following Hodgkin's disease: a 20-year follow-up study.
    van Leeuwen FE; Klokman WJ; Hagenbeek A; Noyon R; van den Belt-Dusebout AW; van Kerkhoff EH; van Heerde P; Somers R
    J Clin Oncol; 1994 Feb; 12(2):312-25. PubMed ID: 8113838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second solid malignancies after combined modality therapy for Hodgkin's disease.
    Doria R; Holford T; Farber LR; Prosnitz LR; Cooper DL
    J Clin Oncol; 1995 Aug; 13(8):2016-22. PubMed ID: 7636543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen?
    Dietrich PY; Henry-Amar M; Cosset JM; Bodis S; Bosq J; Hayat M
    Blood; 1994 Aug; 84(4):1209-15. PubMed ID: 8049435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second malignancies after Hodgkin's disease: the Munich experience.
    Munker R; Grützner S; Hiller E; Aydemir U; Enne W; Dietzfelbinger H; Busch M; Haas R; Emmerich B; Schmidt M; Dühmke E; Hölzel D; Wilmanns W
    Ann Hematol; 1999 Dec; 78(12):544-54. PubMed ID: 10647878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease.
    Mauch PM; Kalish LA; Marcus KC; Shulman LN; Krill E; Tarbell NJ; Silver B; Weinstein H; Come S; Canellos GP; Coleman CN
    Cancer J Sci Am; 1995; 1(1):33-42. PubMed ID: 9166452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hodgkin's disease: study of treatment intensities and incidences of second malignancies.
    Rodriguez MA; Fuller LM; Zimmerman SO; Allen PK; Brown BW; Munsell MF; Hagemeister FB; McLaughlin P; Velasquez WS; Swan F
    Ann Oncol; 1993 Feb; 4(2):125-31. PubMed ID: 8448080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second cancers among long-term survivors of non-Hodgkin's lymphoma.
    Travis LB; Curtis RE; Glimelius B; Holowaty E; Van Leeuwen FE; Lynch CF; Adami J; Gospodarowicz M; Wacholder S; Inskip P
    J Natl Cancer Inst; 1993 Dec; 85(23):1932-7. PubMed ID: 8230284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis.
    Rueffer U; Josting A; Franklin J; May M; Sieber M; Breuer K; Engert A; Diehl V;
    J Clin Oncol; 2001 Apr; 19(7):2026-32. PubMed ID: 11310450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative risk of second cancer in patients in first complete remission from early stages of Hodgkin's disease.
    Henry-Amar M
    NCI Monogr; 1988; (6):65-72. PubMed ID: 3352791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment.
    Swerdlow AJ; Barber JA; Hudson GV; Cunningham D; Gupta RK; Hancock BW; Horwich A; Lister TA; Linch DC
    J Clin Oncol; 2000 Feb; 18(3):498-509. PubMed ID: 10653865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation.
    Swerdlow AJ; Douglas AJ; Hudson GV; Hudson BV; Bennett MH; MacLennan KA
    BMJ; 1992 May; 304(6835):1137-43. PubMed ID: 1392790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease.
    van Leeuwen FE; Somers R; Taal BG; van Heerde P; Coster B; Dozeman T; Huisman SJ; Hart AA
    J Clin Oncol; 1989 Aug; 7(8):1046-58. PubMed ID: 2754447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal cancer after treatment of Hodgkin's disease.
    Birdwell SH; Hancock SL; Varghese A; Cox RS; Hoppe RT
    Int J Radiat Oncol Biol Phys; 1997 Jan; 37(1):67-73. PubMed ID: 9054878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease.
    Beaty O; Hudson MM; Greenwald C; Luo X; Fang L; Wilimas JA; Thompson EI; Kun LE; Pratt CB
    J Clin Oncol; 1995 Mar; 13(3):603-9. PubMed ID: 7884422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of non-Hodgkin's lymphoma in patients treated for Hodgkin's disease.
    Prósper F; Robledo C; Cuesta B; Rifón J; Borbolla JR; Pardo J; Rocha E
    Leuk Lymphoma; 1994 Feb; 12(5-6):457-62. PubMed ID: 8180608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second cancers following pediatric Hodgkin's disease.
    Wolden SL; Lamborn KR; Cleary SF; Tate DJ; Donaldson SS
    J Clin Oncol; 1998 Feb; 16(2):536-44. PubMed ID: 9469338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age.
    Abrahamsen JF; Andersen A; Hannisdal E; Nome O; Abrahamsen AF; Kvaløy S; Høst H
    J Clin Oncol; 1993 Feb; 11(2):255-61. PubMed ID: 8426202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.